HomeCompareRRETY vs ABBV

RRETY vs ABBV: Dividend Comparison 2026

RRETY yields 5.68% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RRETY wins by $12765.42M in total portfolio value
10 years
RRETY
RRETY
● Live price
5.68%
Share price
$6.36
Annual div
$0.36
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12765.52M
Annual income
$12,347,757,806.19
Full RRETY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RRETY vs ABBV

📍 RRETY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRRETYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RRETY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RRETY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RRETY
Annual income on $10K today (after 15% tax)
$482.63/yr
After 10yr DRIP, annual income (after tax)
$10,495,594,135.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RRETY beats the other by $10,495,573,079.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RRETY + ABBV for your $10,000?

RRETY: 50%ABBV: 50%
100% ABBV50/50100% RRETY
Portfolio after 10yr
$6382.81M
Annual income
$6,173,891,288.98/yr
Blended yield
96.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RRETY
No analyst data
Altman Z
2.2
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RRETY buys
0
ABBV buys
0
No recent congressional trades found for RRETY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRRETYABBV
Forward yield5.68%3.06%
Annual dividend / share$0.36$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$12765.52M$102.3K
Annual income after 10y$12,347,757,806.19$24,771.77
Total dividends collected$12736.47M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RRETY vs ABBV ($10,000, DRIP)

YearRRETY PortfolioRRETY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,836$1,135.61$11,550$430.00+$286.00RRETY
2$15,176$2,512.27$13,472$627.96+$1.7KRRETY
3$22,260$6,021.29$15,906$926.08+$6.4KRRETY
4$40,326$16,507.95$19,071$1,382.55+$21.3KRRETY
5$99,048$55,898.58$23,302$2,095.81+$75.7KRRETY
6$362,609$256,627.97$29,150$3,237.93+$333.5KRRETY
7$2,144,074$1,756,082.17$37,536$5,121.41+$2.11MRRETY
8$21,702,675$19,408,516.50$50,079$8,338.38+$21.65MRRETY
9$390,429,861$367,207,998.06$69,753$14,065.80+$390.36MRRETY
10$12,765,517,757$12,347,757,806.19$102,337$24,771.77+$12765.42MRRETY

RRETY vs ABBV: Complete Analysis 2026

RRETYStock

Robinsons Retail Holdings, Inc. operates as a multi-format retail company in the Philippines. The company operates through Supermarkets, Department Stores, DIY Stores, Convenience Stores, Drug Stores, and Specialty Stores segments. It operates supermarkets under the Robinsons Supermarket brand that offer health and wellness, and fresh food products; and department stores under the Robinsons Department Store brand, which provide children's apparel, accessories; homes, snacks and stationery; shoes, bags, luggage and sportswear; ladies and men's apparel, beauty accessories, and furnishings. The company also operates do-it-yourself (DIY) stores under the Handyman Do it Best, True Value, True Home, Robinsons Builders, Home Plus, De Oro Pacific Home Plus, and A.M. Builders' Depot brands that offer DIY and home improvement products; operates and franchises convenience stores under the Ministop name that provide fresh and ready to eat products; and operates drug stores under the South Star Drug name that offer prescription and over-the-counter pharmaceutical products, as well as food, personal care, and other products. In addition, it operates toys and juvenile products under Toys 'R' Us name; consumer electronics and appliances stores under Robinsons Appliances and Saver's Appliance name; beauty products under the Benefit, Shiseido, and Elizabeth Arden brands; mass merchandise stores under the Daiso Japan, Arcova, and Super50 name; pet retail under the Pet Lovers Centre name; and discount store under the No Brand name. It operates 2,208 stores, including 286 supermarkets, 52 department stores, 227 DIY stores, 456 convenience stores, 899 drug stores, and 288 specialty stores. Robinsons Retail Holdings, Inc. was founded in 1980 and is headquartered in Pasig City, the Philippines.

Full RRETY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RRETY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RRETY vs SCHDRRETY vs JEPIRRETY vs ORRETY vs KORRETY vs MAINRRETY vs JNJRRETY vs MRKRRETY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.